Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.
- March quarter revenue exceeds A$100,000, first meaningful commercial sales
- Multi-year contracts secured worth over A$1.4 million in Europe and MENA
- Regulatory approvals in Australia, Europe, UK underpin market access
- Operating costs cut 22%, capital redirected to commercialisation
- Convertible notes extended to June 2026, funding runway under two quarters
Record Quarterly Revenue Signals Commercial Shift
Memphasys Limited (ASX:MEM) has crossed a significant threshold, generating over A$100,000 in revenue for the March 2026 quarter. This marks the company’s first substantial step away from its development-stage roots toward becoming a revenue-generating enterprise focused on commercialising its patented Felix™ System. The revenue milestone is underpinned by repeat cartridge orders from multiple regions, validating clinical adoption and supporting a recurring revenue model.
The company’s Chairman, Dr Lindley Edwards, highlighted the swift transition from strategy to execution, noting that "Memphasys is no longer a development-stage organisation - it is now generating revenue from commercial sales of the Felix™ System." This quarter’s results reflect just four to five months since the strategic realignment announced in late 2025, which prioritised commercialisation, cost discipline, and direct engagement with IVF clinics.
Multi-Year Contracts and Global Market Access
Memphasys has secured over A$1.4 million in multi-year contracted revenue across Europe and the Middle East and North Africa (MENA), with additional agreements in India pending regulatory activation. The company’s CE Mark and UK CE MDR approvals have unlocked immediate commercial sales in Europe and the UK, while TGA approval now enables market entry in Australia. Regulatory submissions are advancing in India, with the Central Drugs Standard Control Organisation (CDSCO) process on track, positioning Memphasys to activate its existing commercial agreements there.
Europe remains the primary growth platform, with initial customer onboarding in Italy and expanding pipelines across multiple markets. The UK market is accessible under existing approvals, extending the company’s footprint. In MENA, Memphasys has maintained momentum with clinical use in Qatar, repeat cartridge orders, and new sales in the UAE and Iraq, while regulatory pathways progress in Egypt and Turkey. This diversified regional approach supports scalable growth, as documented in the company’s continued expansion efforts and MENA commercial traction amid regional challenges.
Operational Efficiency and Funding Considerations
Alongside commercial gains, Memphasys has cut its operating cost base by approximately 22%, saving $57,000 per month through streamlined operations and reallocating capital toward manufacturing and revenue-generating initiatives. This cost discipline aligns with the strategic reset’s emphasis on capital efficiency.
Financially, the company’s cash flow remains negative, with net operating cash outflows of A$724,000 for the quarter and cash reserves of A$420,000 at period end, equating to a funding runway of just under two quarters. Convertible notes held by Peters Investments Pty Ltd were extended to 30 June 2026, maintaining principal and conversion terms but introducing structured interest repayments. Discussions are ongoing to secure an outcome that supports Memphasys’s commercial execution phase. The company has flagged that future funding will not rely solely on equity issuance, instead exploring alternative, non-dilutive funding structures to preserve shareholder value.
Building a Recurring Revenue Model
The Felix™ System’s commercial adoption is gaining traction, with repeat cartridge orders indicating integration into clinical workflows and sustained utilisation. Each clinic onboarded represents a potential recurring revenue stream, driven by procedure volumes that are expected to grow as utilisation expands. While revenue variability is anticipated during this early expansion phase, Memphasys expects increasing predictability and repeatability as more clinics transition from evaluation to routine use.
Looking ahead, the company plans to introduce commercial KPIs in future reports to track contracted revenue, cartridge usage, and active clinics, providing investors with clearer visibility on the recurring revenue model’s development. This approach builds on the momentum detailed in the company’s recent global commercial scale-up update, which outlined multi-market sales and regulatory progress driving growth.
Bottom Line?
Memphasys has moved decisively from strategy to commercial execution, but sustaining growth will hinge on scaling clinic adoption and securing funding beyond mid-2026.
Questions in the middle?
- How quickly will regulatory approval in India unlock new revenue streams?
- What alternative funding structures will Memphasys pursue to extend its runway?
- Can the company maintain cost discipline while scaling commercial operations across diverse regions?